Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma Ltd. has received a patent allowance in Australia for its oral anti-obesity drug Namodenoson, which has demonstrated a promising safety profile. The patent, valid until 2040, covers methods of treating obesity by increasing adiponectin hormone levels to reduce body fat. This advancement positions Can-Fite in the lucrative global obesity treatment market, valued at $12 billion in 2023.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
